Profile data is unavailable for this security.
About the company
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Its pipeline includes three clinical-stage development programs: TERN-701, TERN-601 and TERN-501. TERN-701 is its oral, potent, allosteric BCR-ABL tyrosine kinase inhibitors (TKI) specifically targeting the ABL myristoyl pocket for CML, a form of cancer that begins in the bone marrow and leads to the growth of leukemic cells. TERN-601 is a small-molecule glucagon-like peptide-1 receptor (GLP-1R) agonist that is intended to be orally administered for obesity and other metabolic diseases. TERN-501 is a thyroid hormone receptor beta (THR-b) agonist with high metabolic stability and liver distribution. It is also focused on developing the TERN-800 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity.
- Revenue in USD (TTM)0.00
- Net income in USD-91.06m
- Incorporated2020
- Employees66.00
- LocationTerns Pharmaceuticals Inc1065 East Hillsdale Blvd.Suite 100, Suite 100FOSTER CITY 94404United StatesUSA
- Phone+1 (650) 525-5535
- Fax+1 (650) 275-4395
- Websitehttps://ternspharma.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Contineum Therapeutics Inc | 50.00m | 19.13m | 413.89m | 31.00 | 21.14 | -- | 21.39 | 8.28 | 0.7611 | 0.7611 | 1.99 | 4.66 | -- | -- | -- | 1,612,903.00 | -- | -- | -- | -- | -- | -- | 38.25 | -- | -- | -- | 0.00 | -- | -- | -- | 193.68 | -- | -- | -- |
Biomea Fusion Inc | 0.00 | -127.27m | 425.58m | 110.00 | -- | 3.14 | -- | -- | -3.57 | -3.57 | 0.00 | 3.77 | 0.00 | -- | -- | 0.00 | -90.54 | -- | -107.35 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -43.29 | -- | -- | -- |
Fate Therapeutics Inc | 6.48m | -190.05m | 428.01m | 181.00 | -- | 1.00 | -- | 66.07 | -1.92 | -1.92 | 0.0653 | 3.74 | 0.0108 | -- | 0.9024 | 35,790.05 | -31.67 | -31.82 | -34.36 | -36.05 | -- | -- | -2,933.79 | -359.33 | -- | -- | 0.00 | -- | -34.03 | 68.05 | 42.88 | -- | 21.72 | -- |
Theravance Biopharma Inc | 61.51m | -44.77m | 436.73m | 99.00 | -- | 2.13 | -- | 7.10 | -0.861 | -0.861 | 1.19 | 4.22 | 0.1352 | -- | 4.57 | 621,313.10 | -9.84 | -40.51 | -10.39 | -48.50 | -- | -- | -72.78 | -305.27 | -- | -- | 0.00 | -- | 11.84 | -0.9956 | 40.54 | -- | -19.24 | -- |
Korro Bio Inc | 0.00 | -81.19m | 438.15m | 94.00 | -- | 2.50 | -- | -- | -43.16 | -43.16 | 0.00 | 18.87 | 0.00 | -- | -- | 0.00 | -54.22 | -31.55 | -60.95 | -36.48 | -- | -- | -- | -365.87 | -- | -357.64 | 0.00 | -- | -- | -- | 0.5001 | -- | 78.21 | -- |
Esperion Therapeutics Inc | 229.74m | -86.51m | 441.44m | 240.00 | -- | -- | -- | 1.92 | -1.00 | -1.00 | 1.76 | -1.57 | 0.7353 | 0.7415 | 5.05 | 957,250.00 | -27.69 | -69.45 | -47.42 | -101.81 | 81.85 | -- | -37.65 | -147.44 | 1.78 | -0.6581 | -- | -- | 54.14 | -- | 10.45 | -- | -- | -- |
Precigen Inc | 5.44m | -96.91m | 441.73m | 202.00 | -- | 4.51 | -- | 81.22 | -0.3896 | -0.3896 | 0.0219 | 0.3877 | 0.0289 | -- | 4.12 | 26,925.74 | -51.49 | -31.50 | -64.42 | -38.63 | -4.19 | 44.00 | -1,781.73 | -232.32 | -- | -- | 0.00 | -- | -76.87 | -47.16 | -20.22 | -- | -48.30 | -- |
Terns Pharmaceuticals Inc | 0.00 | -91.06m | 444.33m | 66.00 | -- | 1.88 | -- | -- | -1.26 | -1.26 | 0.00 | 3.66 | 0.00 | -- | -- | 0.00 | -33.23 | -41.34 | -34.55 | -45.70 | -- | -- | -- | -31,010.30 | -- | -- | 0.00 | -- | -- | -- | -49.49 | -- | -26.60 | -- |
Verve Therapeutics Inc | 16.05m | -196.83m | 448.38m | 255.00 | -- | 0.7677 | -- | 27.94 | -2.87 | -2.87 | 0.2309 | 6.96 | 0.0235 | -- | 4.48 | 62,937.25 | -28.80 | -- | -30.24 | -- | -- | -- | -1,226.43 | -- | -- | -- | 0.00 | -- | 505.77 | -- | -27.12 | -- | -- | -- |
AC Immune SA | 16.57m | -61.10m | 457.30m | 133.00 | -- | 2.82 | -- | 27.60 | -0.6852 | -0.6852 | 0.1865 | 1.63 | 0.088 | -- | 61.04 | 124,578.20 | -32.45 | -18.25 | -35.04 | -19.52 | -- | -- | -368.77 | -148.29 | -- | -- | 0.0225 | -- | 276.14 | 15.52 | 23.35 | -- | -15.49 | -- |
ALX Oncology Holdings Inc | 0.00 | -166.20m | 458.48m | 74.00 | -- | 2.69 | -- | -- | -3.71 | -3.71 | 0.00 | 3.27 | 0.00 | -- | -- | 0.00 | -67.73 | -34.34 | -76.12 | -36.47 | -- | -- | -- | -7,238.76 | -- | -- | 0.067 | -- | -- | -- | -30.23 | -- | 14.30 | -- |
Editas Medicine Inc | 69.41m | -166.13m | 460.53m | 265.00 | -- | 1.56 | -- | 6.64 | -2.10 | -2.10 | 0.8765 | 3.58 | 0.1535 | -- | 285.04 | 261,913.20 | -36.74 | -29.85 | -42.55 | -33.19 | -- | -- | -239.36 | -347.71 | -- | -- | 0.00 | -- | 296.32 | 19.59 | 30.49 | -- | -0.1477 | -- |
Alector Inc | 96.41m | -120.61m | 462.65m | 244.00 | -- | 2.59 | -- | 4.80 | -1.39 | -1.39 | 1.12 | 1.86 | 0.1393 | -- | -- | 395,106.60 | -17.43 | -20.00 | -21.55 | -23.81 | -- | -- | -125.11 | -124.07 | -- | -- | 0.00 | -- | -27.36 | 28.52 | 2.19 | -- | 4.79 | -- |
Ocugen Inc | 7.05m | -58.50m | 465.81m | 65.00 | -- | 15.39 | -- | 66.07 | -0.2348 | -0.2348 | 0.028 | 0.1176 | 0.0952 | -- | -- | 108,461.50 | -79.01 | -83.56 | -100.56 | -97.79 | -- | -- | -829.84 | -2,921.94 | -- | -- | 0.0855 | -- | 142.60 | -- | 27.33 | -- | 39.08 | -- |
Tscan Therapeutics Inc | 14.81m | -96.80m | 467.84m | 161.00 | -- | 3.45 | -- | 31.58 | -1.28 | -1.28 | 0.1784 | 2.57 | 0.0715 | -- | -- | 96,181.82 | -46.72 | -- | -52.48 | -- | -- | -- | -653.50 | -- | -- | -- | 0.1974 | -- | 55.52 | -- | -34.73 | -- | -- | -- |
Voyager Therapeutics Inc | 119.04m | -3.04m | 473.22m | 162.00 | -- | 1.39 | 311.74 | 3.98 | -0.1812 | -0.1812 | 2.44 | 6.28 | 0.2954 | -- | 8.27 | 734,839.50 | -0.7554 | 0.6378 | -0.8534 | 0.8203 | -- | -- | -2.56 | 1.30 | -- | -- | 0.00 | 0.00 | 511.16 | 101.01 | 385.14 | -- | -5.43 | -- |
Holder | Shares | % Held |
---|---|---|
Deep Track Capital LPas of 31 Mar 2024 | 6.10m | 9.43% |
Millennium Management LLCas of 31 Mar 2024 | 3.43m | 5.31% |
Soleus Capital Management LP (Investment Management)as of 06 Jun 2024 | 3.34m | 5.17% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 2.96m | 4.57% |
Citadel Advisors LLCas of 31 Mar 2024 | 2.78m | 4.30% |
Fidelity Management & Research Co. LLCas of 31 Mar 2024 | 2.76m | 4.27% |
Franklin Advisers, Inc.as of 31 Mar 2024 | 2.38m | 3.68% |
Point72 Asset Management LPas of 31 Mar 2024 | 2.22m | 3.43% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 2.11m | 3.26% |
Fairmount Funds Management LLCas of 31 Mar 2024 | 2.04m | 3.15% |